Laser-based maze procedure for atrial fibrillation

ABSTRACT

A method and apparatus for treating atrial tissue include positioning a lesion formation tool against the atrial surface. An optical fiber of the tool is energized at a wavelength is selected to have a low absorption in water.

CROSS-REFERENCE TO RELATED APPLICATION

This patent application is a continuation application of commonlyassigned and copending U.S. patent application Ser. No. 10/975,674 filedOct. 28, 2004 and which claims priority to U.S. Provisional PatentApplication Ser. No. 60/516,242 with an assigned filing date of Oct. 31,2003 and filed in the names of Gregory G. Brucker and Robert H. Svenson.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to surgical instruments for laser cardiacablation procedures. More particularly, the invention relates to a wandincluding a fiber optic transmission channel for atrial cardiacablation.

2. Description of the Prior Art

A. Atrial Fibrillation

It is known that at least some forms of cardiac arrhythmia are caused byelectrical impulses traveling through the cardiac muscle tissue byabnormal routes. In a normal, non-arrhythmic heart, electrical nerveimpulses travel in an orderly and well-defined fashion through thesinoatrial node and then through the atrioventricular node in order tocreate an orderly flow of nerve impulses that lead to contraction in theheart.

In cardiac arrhythmia, cardiac impulses travel disorderly andundesirable paths through the cardiac tissue leading to disorderly andinefficient contraction of heart muscle. These fibrillations prevent theheart from pumping blood efficiently and can lead to death.

B. Maze Procedure—Generally

One technique for treating atrial fibrillation is to surgically createlines in the heart muscle tissue (myocardium) whereby electricalconduction of nerve impulses is blocked or rerouted. This technique forcreating lines of electrical blockage is referred to as the Mazeprocedure.

Initial approaches to performing the Maze procedure involved invasivesurgery in which a series of linear incisions are made in the cardiactissue and then sutured together. The lines of scar tissue that form inthe incisions do not conduct nerve impulses and are intended to preventdisorderly contraction of the atrial tissue.

In a typical Maze procedure, up to six non-conductive lines arerequired. Each of the non-conductive lines is typically severalcentimeters in length. Once these lines scar and heal, they disruptelectrical pathways that may support atrial fibrillation. Examples ofthe Maze procedure and other surgical techniques for treating atrialfibrillation are described in Chiappini, et al., “Cox/Maze III OperationVersus Radiofrequency Ablation for the Surgical Treatment of AtrialFibrillation: A Comparison Study”, Ann. Thorac. Surg., No. 77, pp. 87–92(2004) and Cox, “Atrial fibrillation II: Rationale for surgicaltreatment”, J. Thoracic and Cardiovascular Surg., Vol. 126, No. 6, pp.1693–1699 (2003).

C. Less Invasive Maze Procedure Technologies

Less invasive ablation techniques have also been utilized to perform theMaze procedure. In such techniques, the surgeon typically drags anelectrode in a linear fashion along the endocardial (internal) orepicardial (external) surface to produce a series of focal lesions. Thescaring created by the focal lesions is hopefully contiguous andnon-conductive of electrical impulses. For endocardial use, standardablation catheters or catheters with extended distal electrodes areemployed. Epicardially, specially designed handheld probes with a distalelectrode for the application of ablating energy are often used.

For the greatest likelihood of success in a Maze procedure, it isparticularly important that the lesions created be transmural. Atransmural lesion extends through the full wall thickness of the cardiacmuscle at the location of the lesion. One factor that obstructsobtaining transmural lesions from an epicardial approach of the heart isthe cooling effect of blood in and around the heart. This is aparticular difficulty when radio frequency (RF) energy is employed. Theapplication of RF energy relies exclusively on thermal diffusion tocreate transmural lesions. The cooling effect of blood within the atriumtends to limit the depth to which thermal lesions can be formed.

It is desirable to create a full thickness transmural lesion butundesirable to perforate the atrial wall. Perforation of the atrial wallleads to a weakening of the heart structure as well as significantbleeding during surgery that must be controlled.

Additionally, producing transmural lesions with RF energy tends to heatthe surface tissue at the point of probe contact this. This tends tocreate burns and adhesion between the probe and the heart tissue. Suchadhesions can insulate the probe from the heart tissue blocking theefficient application of energy. These procedures are also a problem forthe surgeon and staff who often must stop to clean the tip of the probe.

A discussion of techniques and technologies for treating atrialfibrillation is set forth in Viola, et al., “The Technology in Use forthe Surgical Ablation of Atrial Fibrillation”, Seminars in Thoracic andCardiovascular Surgery, Vol. 14, No. 3, pp. 198–205 (2002). Viola et al.describe numerous ablation technologies for treating atrial fibrillationwith the Maze procedure. These include cryosurgery, microwave energy,radiofrequency energy, and laser ablation.

D. Laser Ablation and the Maze Procedure

i. Treatment of Atrial Fibrillation with Laser Energy

The use of lasers in treating atrial fibrillation is desirable. Laserablation is fast and the resulting lesion is narrow. Viola, et al., “TheTechnology in Use for the Surgical Ablation of Atrial Fibrillation”,Seminars in Thoracic and Cardiovascular Surgery, Vol. 14, No. 3, pp.201, 204 (2002). However, in the prior art, laser ablation for treatingatrial fibrillation has been troublesome.

Viola et al. discuss problems associated with the use of laser energy totreat atrial fibrillation. These concerns are directed to safety andreliability and note that lasers are prone to overheating because of theabsence of a self-limiting mechanism. The authors note that over-heatingwith lasers can lead to crater formation and eventually to perforation,especially when using pin-tip devices. Viola, et al., supra, at p. 203.The authors note that the high power of laser ablation (described as 30to 80 Watts) results in the laser technique not being widely clinicallyapplied. Id., at p. 201. The mechanical effects resulting from directheating of the myocardial tissue with laser energy results in cellularexplosions caused by shock waves. Viola, et al., supra, at p. 201.

The possibility for perforation of the myocardium with laser energyraises a particular concern for treating atrial fibrillation. Themyocardial wall of the atria is quite thin (e.g., about 2 mm inthickness in some locations). A coring of the myocardium by a lasercould result in a full wall thickness perforation and resulting leakageof blood.

Viola et al. note the development of a long probe laser that allowsdiffusion of the laser thermal energy over the long probe tip in aunidirectional fashion. Id., at p. 201. While not mentioning the sourceof this long probe tip, it is believed by the present inventors to bereferring to the atrial fibrillation laser of CardioFocus, Inc., Norton,Mass. (USA) as described in U.S. Patent Application Publication No.2004/6333A1 in the name of Arnold, et al. (published Jan. 8, 2004) andU.S. Pat. No. 6,579,285 issued to Sinosky. Unfortunately, thistechnology defocuses energy and increases the risk (particularly on abeating heart) of creating a lesion that is less than transmural.

ii. Inapplicability of Ventricular Laser Treatment

Lasers have been effectively used for treating ventricular tachycardia.An example of such is described in U.S. Pat. No. 5,104,393 to Isner etal. dated Apr. 14, 1992.

Unfortunately, while such laser treatments are appropriate for treatingthe left ventricle. They are not applicable to treating the atria.

The myocardial wall of the left ventricle is substantially thicker thanthe atria. Therefore, perforation risks are less. Also, in a ventriculartreatment, the laser is targeted against a tissue area for substantialperiods of time (e.g., about two minutes). To accomplish this, thelasers have a fixation member at the laser tip. (see, e.g., element 42in the '393 patent). The lasers may also be provided with a temperaturesensing tip as described in U.S. Pat. No. 5,830,209 to Savage et al.dated Nov. 3, 1998. Temperature probes provide a temperature profile atthe tissue treatment site. U.S. Pat. No. 5,827,267 to Savage et al.dated Oct. 27, 1998 teaches a multi-fiber laser with recirculatingcoolant contained by a quartz lens and a 50 to 100 watt power sourcewith irradiation up to ten minutes.

The aforementioned lasers are catheter delivered to project laser energyto the interior (endocardial) surface of the heart in the ventricle. Intreating tachycardia as described, the laser is intended to create alesion of necrosed tissue at a discrete target site. To accomplish this,a high power laser is provided with an anchor or fixation device to holdthe laser tip at the target site for a prolonged period of laserirradiation.

Ventricular treatment lasers are not applicable to treating atrialfibrillation. In treating atrial fibrillation, a long, narrow,transmural lesion is desired to be formed in a pathway consistent withthe Maze procedure. The high power laser of the ventricular treatmentlasers presents risk of damage and perforation of the thin-walled atriumas noted by Viola, et al. Further, the single-point treatment ofventricular lasers (created with the assistance of myocardial fixation)is inappropriate to the objectives of the Maze procedure and the tips ofsuch lasers are not optimized for atraumatic movement over theepicardial surface of the atria.

In the foregoing, applicants have referred to the use of lasers inatrial fibrillation as “ablation” techniques. While the use of the term“ablation” is a common usage when describing atrial fibrillationtreatments, such usage is an unfortunate misnomer. In treating atrialfibrillation, there is no intent or desire to ablate tissue to theextent that term implies removal of tissue. In fact, in a strict sense,ablation is to be avoided. As noted in Viola et al, it is undesirable tocreate perforations through laser ablation. Instead, the desire is tocreate a full myocardial wall thickness (i.e., “transmural”) lesion ofscar tissue or necrosed myocardial tissue which is narrow and remains insitu in the surrounding myocardium to act as a barrier to undesirabletransmission of electrical or neural impulses through the myocardium.

In the strict sense of tissue removal, ablation lasers have been used inthe ventricle in transmyocardial revascularization (“TMR”) procedures.In TMR procedures, the object is to form a bore from the left ventriclepartially through the myocardium with the hope the bore will facilitatethe flow of oxygenated blood into ischemic myocardial tissue. Of course,such technology is not applicable to atrial fibrillation treatments werebore formation (or perforations) are to be avoided.

In all types of laser treatments or RF electrode treatments, it isimportant that the apparatus not damage the tissue through mechanicaldamage. In ventricular lasers, the traumatic tip does not risk damage tothe endocardial tissue since it is immobilized in place with an anchoror fixation as described in the afore-mentioned U.S. Pat. No. 5,104,393.In the afore-mentioned U.S. Patent Application Publication No.2004/6333A1, such risks are minimized by laying the diffusing probe overthe tissue area.

In the present invention, it is contemplated to draw the tip of a laserwand over the surface of the heart in the region of the atria. In doingso, care must be taken to minimize risk of injury to the atria. Forexample, the atria are very thin walled. Also, while not as abundant inthe atria as in the ventricle region, superficial blood vessels resideon the epicardial surface. A moving object should minimize snags ortears.

From the above, while laser treatment of atrial fibrillation isdesirable, existing technology has been inadequate. It is an object ofthe present invention to provide an apparatus and method for treatingatrial fibrillation with the benefits of a laser treatment. The surgicalart would benefit from a laser probe for creating transmural,non-perforating lesions without the problems of sticking or snagging onthe atrial wall tissue. Further, it is desirable that the probe itselfnot heat up and that energy be efficiently applied to the heart tissue.

E. Conductivity Verification

A further difficulty with creating linear nonconductive lesions is theinability to verify that a truly nonconductive lesion has been produced.If a transmural lesion is not properly formed in accordance with theMaze procedure, the treatment for atrial fibrillation may not besuccessful. This could require a second surgical procedure. It would behelpful if the surgeon could promptly discern whether a particularlinear lesion is truly non-conducting at the time of the originalprocedure to permit correction at that time. This would enable promptre-treatment if necessary.

F. Additional Cardiac Ablation Technology

A large variety of devices for cardiac ablation exist in the art.Devices for cardiac ablation combining electrodes and laser include:U.S. Pat. No. 4,785,815 issued to Donald Cohen, U.S. Pat. No. 5,172,699issued to Robert Svenson et al, U.S. Pat. No. 5,306,274 issued to GaryLong. U.S. Pat. No. 5,769,843 issued to George Abela et al, U.S. Pat.No. 5,824,005 issued to Massoud Motamedi et al, U.S. Pat. No. 6,024,739issued to Dean Ponzi et al and U.S. Pat. No. 6,200,310 B1 issued toShlomo Ben-Haim et al.

Devices for cardiac ablation including electrodes but no laser include:U.S. Pat. No. 5,354,296 issued to David Turkel, U.S. Pat. No. 6,063,081issued to Peter Mulier et al., U.S. Pat. No. 6,161,543 issued to JamesCox et al., and U.S. Pat. No. 6,231,518 B1 issued to James Grabek et al.

Device employing laser for cardiac ablation include: U.S. Pat. No.4,693,244 to Daikuzono, U.S. Pat. Nos. 4,985,028 and 5,104,393 toJeffrey Isner et al., U.S. Pat. No. 5,282,798 issued to Bruse et al.,U.S. Pat. No. 4,955,267 issued to Jacobs, et al., U.S. Pat. No.5,389,096 issued to Michael Aita et al., U.S. Pat. No. 5,897,551 issuedto Everett, et al., U.S. Pat. No. 5,951,541 issued to Simpson, et al.,U.S. Pat. No. 6,066,131 issued to Richard Mueller et al., U.S. Pat. No.6,110,167 issued to Cozean, et al., U.S. Pat. No. 6,135,996 issued toKolesa et al., U.S. Pat. No. 4,693,244 issued to Daikuzuno, U.S. Pat.No. 5,046,810 issued to Steiner et al and U.S. Pat. No. 5,534,000 issuedto Bruce.

Devices for intracardiac use as catheters include: U.S. Pat. No.5,782,828 issued to Peter Chen, U.S. Pat. No. 5,800,428 issued to DaleNelson et al and U.S. Pat. No. 6,063,080 issued to Dale Nelson et al.

Devices for epicardial procedures include: U.S. Pat. Nos. 5,380,316 and5,925,033 issued to Michael Aita et al., U.S. Pat. No. 5,728,091 alsoissued to Sam Payne et al, U.S. Pat. No. 6,231,568 B1 issued to MarvinP. Loeb et al, U.S. Pat. No. 6,237,605 B1 issued to Matthias Vaska etal.

SUMMARY OF THE INVENTION

According to a preferred embodiment of the present invention, a methodand apparatus are disclosed for treating a body tissue in situ (e.g., anatrial tissue of a heart to treat) atrial fibrillation. The method andapparatus include identifying a patient with atrial fibrillation andaccessing a surface of the tissue. A lesion formation tool is positionedagainst the accessed surface. The tool includes an optical fiber forguiding a coherent waveform of a selected wavelength to a fiber tip fordischarge of light energy from the fiber tip. The wavelength is selectedfor the light energy to penetrate a full thickness of the tissue to forma volume of necrosed tissue through the thickness of the tissue. Thetool further includes a guide tip coupled to the fiber tip. The guidetip is adapted to have a discharge bore aligned with the fiber tip todefine an unobstructed light pathway from the fiber tip to the tissuesurface. The guide tip is further adapted to be placed against thetissue surface with the guide tip slidable along the tissue surface inatraumatic sliding engagement. The lesion formation tool is manipulatedto draw the guide tip over the tissue surface in a pathway whilemaintaining the discharge bore opposing the tissue surface to form atransmural lesion in the tissue extending a length of the pathway.

In an alternate embodiment, an operator can manipulate an angle of thetool tip relative to a handle. In a still further embodiment, the toolhas sensing electrodes to allow for immediate verification of thenonconductive nature of a lesion produced.

In a detailed preferred embodiment, the tool includes a fluid pathwayfor perfusing a liquid around the location where the lesion is created.The tool includes an optical fiber, a support assembly including atubular shaft and handle, an internal lumen for a flushing fluid and anoptical connector for interfacing to a laser. The tip assembly includesan optical fiber that couples the probe to a laser and transmits laserenergy to the tip. Preferably the tip of the probe is shaped to allowfor easy movement across the surface of the heart. In addition, the tipalso spaces the fiber at a fixed position relative to the tissue surfaceto optimize achievement of transmural lesions without perforation of thetissue.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a top, right side and distal end perspective view of a lasersurgical wand according to a first embodiment of the present invention;

FIG. 2 is a schematic representation of the laser surgical wand of FIG.1 connected to a laser energy source, a coolant fluid source and anoptional monitoring apparatus;

FIG. 3 is a perspective longitudinal section view of a distal tip of thewand of FIG. 1;

FIG. 4 is a longitudinal sectional view of the distal tip of the wand ofFIG. 1 positioned against a tissue surface with an axis of a laserenergy discharge substantially perpendicular to the tissue surface;

FIG. 5 is the view of FIG. 4 with the axis of the laser energy at anacute angle to the tissue surface;

FIG. 6 is the view of FIG. 1 showing an alternative embodiment of thelesion formation tool to permit adjustability of an angle of a dischargeguide tip;

FIG. 7 is a view similar to FIG. 6 and showing an alternative embodimentof adjustability feature;

FIG. 8 is a view taken along line 8—8 of FIG. 7;

FIG. 9 is the view of FIG. 6 showing a still further alternativeembodiment for adjustability;

FIG. 10 is the view of FIG. 6 showing a yet further alternativeembodiment of an adjustability feature;

FIG. 11 is a view taken along line 11—11 of FIG. 10;

FIG. 12 is the view of FIG. 6 showing a still further embodiment of anadjustability feature;

FIG. 13 is a view taken along line 13—13 of FIG. 12;

FIG. 14 is the view of FIG. 6 showing a still further embodiment of anadjustability feature;

FIG. 15 is the view taken along line 15—15 of FIG. 14;

FIG. 16 is the view of FIG. 1 showing a visualization fiber near adistal end of a shaft;

FIG. 17 is the view of FIG. 16 showing an alternative embodiment of avisualization fiber;

FIG. 18 is the view of FIG. 3 showing multiple fibers in an alternativeembodiment of the invention;

FIG. 19 a sectional view similar to that of FIG. 3 showing analternative tip of the laser surgical wand of the present invention andillustrating optional sensing electrodes;

FIG. 20 is the view of FIG. 19 with a further embodiment illustratingoptional electrodes on mechanical extensions.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Referring now to the drawing figures in which identical elements arenumbered identically throughout, a description of a preferred embodimentof the present invention will now be provided. In the preferredembodiment, the invention is described as a lesion formation tool in theform of a surgical wand for applying laser energy to the epicardialsurface of the heart to create a transmural ablation line along theheart. It will be appreciated that the atraumatic nature of the distaltip of the invention, as will be described, could also be used in a toolfor creating such a line by applying the energy against the endocardialsurface of the heart. As used in this application, the term “ablation”is used in the context of creating necrosed tissue in the myocardiumwhile avoiding tissue perforation or removal.

Atraumatic Atrial Laser

Referring first to FIGS. 1–3, a lesion formation tool is shown as alaser surgical wand 10 having an elongated shaft 12 with a distal end 14and a proximal end 16. A handle 18 is carried on the shaft 12 at theproximal end 16. A guide tip 24 is connected to the distal end 14.

A waveguide in the form of an optical fiber 20 passes axially throughthe entire length of the shaft 12 and substantially though the entirelength of the guide tip 24. The fiber 20 resides within aligned bores26, 27 (FIG. 3) formed through the length of the shaft 12 and guide tip24.

The fiber 20 is retained in the bores 26, 27 by a fixation collar 21shown in cross-section in FIG. 3 (it will be appreciated the collar 21is symmetrical about axis A—A). The collar 21 is a cylinder having anouter diameter sized to be snugly received within the bore 26 and aninner diameter to snugly receive the fiber 20. This collar 21 holds thefiber axis aligned with the axis of the shaft 12 and retains the fibertip 22 the desired spacing from the distal edge of the guide tip 24 aswill be described. A plurality of holes 23 are formed through the lengthof the collar 21 and permit fluid flow through the bores 26, 27 as willbe described.

The fiber 20 (FIG. 3) terminates at a fiber tip (or discharge end) 22.The fiber tip 22 is cleaved or polished flat and perpendicular to thelongitudinal axis A—A of the fiber 20. The aligned bores 26, 27 haveinternal diameters greater than the external diameter of the fiber withopposing surfaces of the fiber 20 and each of the shaft 12 and guide tip24 defining an annular fluid passage surrounding the fiber 20 throughoutits length.

FIG. 2 schematically illustrates the laser wand connected to supportingapparatus for use in treating atrial fibrillation. In FIG. 2, the heart100 is shown schematically and divided into left and right atria 102,104 and left and right ventricles 106, 108.

A coupling member 28 is connected to the proximal end 16 of the shaft 12by a flexible connecting tubing 30. In FIG. 1, the tubing is shownsevered at the proximal end 16. The tubing is an extrusion from theproximal end and has an internal diameter greater than the externaldiameter of the fiber 20. The tubing 30 acts to protect the fiber 20from mechanical injury. Opposing surfaces of the tube 30 and opticalfiber 20 define an extension of the fluid pathway 26 through the tubing30.

A power source 32 (FIG. 2) is connected to the wand 10. The power source32 is a laser energy source of the requisite wavelength and power forforming transmural lesions as will be described. A flexible tubing 34connects the laser energy source 32 to a side 28 a of the couplingmember 28. The fiber 20 extends through the tubing 34 and is connectedto the power source by a fiber optic connector 33.

FIG. 2 also shows an optional electrophysiology signal generator andmonitor 36 connected via a cable to an electrical connector 28 b of thecoupling 28. Such coupling electrically connects the generator/monitor36 to optional internal wires (not shown) of the wand 100 to optionalelectrodes carried on the guide tip 24. This optional feature will bediscussed with reference to FIGS. 19 and 20.

Any wavelength suitable to create necrosed tissue in the myocardiumwithout tissue removal could be used. In a preferred embodiment, thewavelength is a near-infrared wavelength selected to have a very lowabsorption and very high scatter in myocardial tissue. Biological tissue(such as the myocardium) is largely water. Wavelengths in the ranges ofbetween about 470 to about 900 nanometers and between about 1050 toabout 1150 nanometers are known to penetrate water with low absorption(e.g., less than about 30% absorption). Lasers in CardiovascularMedicine and Surgery: Fundamentals and Techniques, George S. Abela, M.D., Editor, Kluwer Academic Publishers, 101 Philip Drive, AssinippiPark, Norwell, Mass. 02061 USA, p. 28 (1990). More preferably, thewavelength is selected from the ranges of 790 to 850 nanometers (whichrange corresponds to commercially available medical diode lasers) and1050 to 1090 nanometers (which range corresponds to Nd:YAG laserscommonly used in other medical procedures). A laser energy source with awavelength selected from these ranges will penetrate the full thicknessof the myocardium and result in a transmural lesion (i.e., afull-thickness necrosis of myocardial tissue in the atrium). Furthersuch a wavelength minimizes carbonization of the tissue and perforationof the myocardial tissue. Such laser emissions are substantiallycoherent.

Only one wavelength need be passed through the fiber 20 to treat thetissue as described. Conveniently, this may be referred to as thetherapeutic wavelength. The therapeutic wavelengths described areinvisible to the human eye. It may also be desirable to concurrentlypass a visible wavelength (the “targeting” wavelength) through the fiber20 to permit an operator to visualize the precise location on the hearttissue being targeted by the therapeutic wavelength. With a targetingwavelength, if an operator holds the guide tip 24 at too great an angleto the heart surface, the visible light can escape the tip 24 giving theoperator a visual signal that the tip 24 is at too great an angle.

The laser surgical wand 10 is also connected to a fluid source 40 whichis a reservoir of a cooling fluid as will be described. An infusionfluid pump 42 urges fluid from the source 40 through a tubing 44 to afluid inlet 28 c of the coupling member 28. Therefore, the fluid isadmitted to flow through the annular passages 26, 27 and dischargethrough the guide tip 24.

As will be more fully described, the fluid flow cools the material ofthe guide tip 24, washes biological material (e.g., blood, tissue debrisor the like) from the light path between optical fiber 20 and the heartsurface, and acts as a lubricant to further facilitate atraumaticgliding movement of the guide tip 24 over the surface of the heart.

The washing action of the fluid maximizes the laser energy impinging onthe surface of the heart. Additionally, this fluid provides a means tocool the tissue in the region of the guide tip 24 to help ensure thattissue carbonization and subsequent vaporization of cardiac tissue donot occur. This substantially reduces the likelihood of perforation ofthe heart wall. Also, the fluid forms a protective layer at thedischarge end 22 of optical fiber 20 which reduces the likelihoodbiological residue will impinge on and/or adhere to the discharge end 22which can otherwise cause spalling of the fiber face 22 and reduceoptical transmission of laser energy.

Since the fluid flows into the body of the patient, the fluid should bemedical grade and biocompatible. Also, the fluid should have a lowabsorption of the laser energy. A preferred fluid is a physiologicalsaline solution which may be supplied at ambient temperature.

The pump 42 includes control knobs and the like to permit an operator toset or modify a flow rate of the fluid. For example, an operator can setfluid flow as low as 0.2 milliliters per minute or as high as 20milliliters per minute or any other desired setting. As will bedescribed, some flow is preferred to cool the tip and wash the end ofthe fiber. For treating thin atrial tissue, the flow rate is preferablyabout 10 milliliters per minute which provides the afore-mentionedbenefits but minimizes excessive fluid infusion into the patient.

In the description of FIG. 2, it will be appreciated thatgenerator/monitors 36, pumps 42, reservoirs 40, laser power sources 32,coupling 28 and cables 34, 38 and tubing 44 are commercially availableand form no part of this invention per se. The handle 24 and coupling 28may be constructed of a rigid plastic such as a polycarbonate. Theconnecting tubing and fiber sheath may be constructed from extrudedtubing made from a flexible plastic such as PVC. Other materials, suchas plastics or composites, may be employed in various members. Thematerials employed must have sufficient mechanical strength to endurethe forces involved in applying the laser surgical wand 100 to a beatinghuman heart. In addition, materials must be appropriate to withstand therigors of sterilization and meet all biocompatibility requirements.

In the embodiment of FIG. 1, the shaft 12 is made of a metallic materialsuch as stainless steel. Additional embodiments of differentconstruction will later be described.

As shown in FIG. 1, the shaft 12 maintains the axis A—A of fiber 20 atthe guide tip 24 at an angle A to the axis B—B of the shaft 12 at thehandle 18. In the embodiment of FIG. 1, this angle A is fixed. It willbe appreciated other angles could be selected. In later embodiments,adjustability of the angle A is described.

The curvature of the shaft 12 at the distal end 24 of the laser surgicalwand 10 is beneficial for assisting the physician in aligning the guidetip 24 in a perpendicular orientation to the myocardial tissue whilemaintaining a comfortable grip for the physician at the handle 18. Aperpendicular alignment provides optimal coupling efficacy between thelaser energy exiting the laser surgical wand 10 and the targeted cardiactissue. The angle A can range from 0 to 135 degrees but is preferablybetween 20 and 90 degrees.

Referring to FIG. 3, the guide tip 24 is shown in longitudinalcross-section. The guide tip 24 is formed of plastic which is secured tothe distal end 14 of the shaft 12. The guide tip 24 can be secured tothe distal end 14 by any suitable means (e.g., threaded, adhered orother attachment means). The guide tip 24 has a centrally extendinglumen 27 with a proximal end 27 a in alignment with the annular passage26 of the shaft 12. The stiffness of the fiber 20 maintains it alignmentwith the fiber axis A—A coaxial with the axis of the bore 27.

The optical fiber 20 extends through the lumen 27 with the discharge end22 slightly spaced from a distal edge 50 of the guide tip 24. While thedischarge end 22 could terminate at the distal edge 50, it is preferablyspaced receded into the guide tip 24 by a spacing S of about 0.5 mm (andmost preferably about 0.25 mm) from the distal edge 50.

It is desirable to have as close a spacing S of the discharge tip 22 tothe distal edge 50 as possible to maximize laser energy penetration ofmyocardial tissue. The power density impinging on cardiac tissuedecreases rapidly with increasing spacing S. However, a small spacing S(about 0.25 mm preferred) from the surface of the heart is desirable toprevent coagulation of biological products onto the face of the opticalfiber. Build-up of tissue is undesirable because it can causecarbonization and spalling of the optical fiber face which reduces laserenergy output from the optical fiber. If sufficient biological materialis present in the vicinity of the optical fiber face, overheating andsubsequent melting of the tip 24 can occur.

As shown in FIG. 3, the lumen 27 widens in a conical shape 29 to thedistal edge 50. In a preferred embodiment, the widening starts adistance D of 1.0 mm proximal to the discharge tip 22 of the fiber 20and widens at an angle of 45 degrees (measured as the angle of theconical surface 29 to the fiber axis A—A) to a maximum diameter at alumen distal end 27 b at the edge 50. At the proximal end 29 a, the borehas a diameter of about 1.2 mm. At the distal end 27 b, the bore 27 hasa diameter of about 3.6. In a preferred embodiment, the fiber 20 may beeither a 600 micron (1.0 mm) or 400 micron (0.72 mm) fiber.

The widening of the lumen 27 serves several purposes. Preferably, thelaser energy source is a commercially available diode laser. Such laserenergy sources have a high divergence angle for laser energy exiting thedischarge tip 22 of the fiber 20. The widening of the distal end of thelumen 27 accommodates the discharge divergence of the laser energy.Further, the widening increases the surface area of the lumen 27 at thedistal edge 50. This increases the area of the heart surface beingwashed by the fluid passing through the lumen 27.

At the distal edge 50 of the guide tip 24, the guide tip 24 does notpresent a flat surface opposing the heart tissue. Instead, the distaledge 50 is a radiused edge which presents a rounded ring opposing theheart surface. The edge 50 is radius at a radius of 0.75 mm over an arcof 90 degrees with an internal edge 50 a beginning at the maximumdiameter 27 b of the lumen 27. The radiused or rounded edge 50 presentsan atraumatic surface abutting the heart throughout the operating angleof the guide tip 24. The operating angle is the preferred angle of theaxis A—A of the fiber 20 in the guide tip 24 to the surface of theheart. Preferably, this is within 45 degrees off perpendicular and, morepreferably, within 30 degrees of perpendicular to ensure adequatecoupling of the optics with the heart tissue. The outer surface 31 ofthe guide tip 24 is cylindrical and parallel to the fiber axis A—A. Therounded edge 50 blends into the cylindrical surface at 33 with a tangentof the edge 50 co-linear (in the same plane as axis A—A) with thecylindrical surface 31 so that no sharp edge is presented.

The guide tip 24 is circular in cross-section (taken perpendicular tothe fiber axis A—A). The tip 24 has an outer cylindrical diameter of 5mm and a cylindrical height of 6 mm. The discharge lumen 29 has aconical axis co-linear with the fiber axis A—A (which is collinear withthe axis of light discharged from the fiber tip 22). The fluid flowsfrom the guide tip in a direction parallel with axis A—A and flowsradially outwardly in response to impinging upon the heart surface.

To further enhance the atraumatic nature of the guide tip 24, the tip 24is formed of a soft material having a low coefficient of friction orlubricious-like nature against the heart tissue. Also, it is desirablethat the material of the tip 24 be as transparent as possible to thetherapeutic wavelength. For the preferred wavelengths described above, apreferred material is Delrin® acetal of DuPont Co., New Jersey (USA).While such material is generally transparent to the preferred laserenergy wavelengths, the material may absorb some of the energy.Therefore, the fluid flowing through lumen 27 acts to cool the guide tip24 as it flows through and around the tip 24.

In operation, the laser source 32 is adjusted to an appropriate powerlevel, for example, from five to fifty watts. In addition, anappropriate flow rate for liquid cooling and flushing is set on infusionpump 42. An appropriate flow rate, for example, preferably is in therange of one to thirty milliliters per minute. The laser surgical wand100 is then purged of air.

With the laser power source 32 and pump 42 activated, the surgeonapplies the laser surgical wand 100 to epicardial tissue of the left orright atrium 102, 104 while tip 24 is in contact with the exteriorsurface of the heart 100 and held within the desired angle (preferablyperpendicular or with 30 degrees of perpendicular) to the heart surface.The laser tip 22 is spaced from tissue by an unobstructed light pathwaywhich is cleansed by the fluid from reservoir 40 (such fluid beingnon-absorbing or only minimally absorbing to the selected wavelength).With the present invention, the light impinging on the heart surface isa point which is then moved over the surface in a linear or curved path.Due to the unobstructed path, the light is a non-diffused or unmodifiedbeam directed at the heart surface either perpendicularly of at an angleas described above.

The physician moves the probe 10 along the exterior surface of the heartin order to create lines of ablated (i.e., non-conducting) tissue byraising the temperature of the cardiac tissue to that required toachieve cellular death (typically 55° C.). For effective treatment ofatrial fibrillation, the lines of ablated tissue must be transmural(i.e., cellular death extends the full thickness of the atrial tissue)and contiguous (no gaps of surviving tissue along the lines of cardiacablation). The physician creates a pattern of lines which effectivelydivides the atria into electrical compartments. Commonly used patternsare called the MAZE pattern with its derivative patterns. If desired,the physician can easily re-trace the created pattern with additionalapplication of energy. With the current invention, the physician caneasier create complex, non-linear curved patterns or pathways aroundanatomical features (such as pulmonary veins).

Advantageously, the laser surgical wand 10 of the present inventionutilizes laser energy that penetrates more deeply and is more highlyfocused than radio frequency energy. Laser energy is light that isconverted into heat when absorbed by cardiac tissue. This allows theapplied laser energy to first be scattered through the full thickness ofthe myocardium as light because of the optical properties of cardiactissue and, secondarily, to be diffused as heat, because of the thermalproperties of cardiac tissue. This allows for formation of lesions whichhave a smaller width than those created with more traditional radiofrequency energy. Additionally, use of laser energy allows the creationof transmural lesions while there is full cardiac flow in the heart.

Radio frequency energy, on the other hand, relies on thermal diffusionto transmit energy from the epicardium to the endocardium. Because heatdiffuses equally in all directions, radio frequency lesions are widerand its energy less focused than laser energy, especially in a unipolarmode. As a result, the cooling effect of the blood flow within the atriaprevents subendocardial tissue from achieving the requisite temperaturefor cellar death. Therefore, to produce transmural lesions with radiofrequency energy requires that cardiac flow be stopped by placing thepatient on cardiac bypass. Otherwise, the surface of the heart must beheated to above a maximum (e.g., 75 degrees C.) to provide an adequatetemperature gradient across the myocardium. However, at suchtemperatures, steam is created resulting in undesirable tissue damageand possible perforation. Any tissue removal in the thinned-walledatrium (about 2 mm thick in places) is undesirable.

The guide tip 24 permits the physician to slide the guide tip 24 overthe heart surface in an atraumatic manner as the surgeon creates theablation lines. FIGS. 4 and 5 illustrate the gliding movement. FIG. 4shows the gliding motion (Arrow M) while the guide tip 24 is held in amost preferred perpendicular alignment to surface H the heart. FIG. 5illustrates the gliding motion with the guide tip 24 at a less preferredbut acceptable angle to the heart. In both, the rounded edge 50 opposesthe heart surface to present a smooth atraumatic surface to the heartwith no sharp edges opposing the heart. With an operating laser power ofabout 25 watts, the surgeon can create an ablation line by gliding theguide tip 24 over the heart surface at a rate of between about 1 to 5 cmof linear travel per minute.

Fluid flow through the lumen 27 cools the heart surface (to preventcarbonization) and cools the guide tip 24 while washing debris from awide area around and below the fiber discharge end 22. Further, as thefluid flows between the guide tip 24 and the heart, the fluid acts as alubricant further facilitating atraumatic gliding motion of the guidetip 24 over the heart surface.

Unlike laser treatment for ventricular ablation, the laser of thepresent invention is in continuous liner motion along the surface of theheart. The novel guide tip 24 permits atraumatic linear sliding motionnot safely possible with prior art ventricular lasers which are adaptedfor anchoring in place at a specific location on the ventricular wall.

Optional Adjustable Tip

Referring to FIGS. 6–15, an additional modifications are is shownwhereby component parts (e.g., the shaft 12) are constructed usingmalleable construction techniques, such as corrugations rather than arigid tubular material. Alternatively, a highly elastic metal such asnitinol could be use. Nitinol is a well-known alloy of nickel andtitanium which is malleable and highly elastic and can be formed withshape-memory properties. Malleability allows the shape of tip to bechanged during a procedure. The ability to reconfigure tip allowssurgeons to set the optimal geometric relationship between the lasersurgical wand and the heart for applying laser energy. The mazeprocedure requires that linear lesions be placed on both the front andback side of the atria. When viewed physiologically, encirclement of thepulmonary veins on the backside of the heart is made easier if the shapeis more acute than the shape required for lesions on the front side ofthe atria. By actively shaping tip, procedure time is decreased and thelikelihood of perforation is reduced making the procedure faster andsafer for the patient.

In the embodiments of FIGS. 6–15, elements in common with the previousdescribed embodiment are numbered identically throughout with theaddition of subscripts to distinguish the embodiments.

In FIG. 6, the shaft 12, from the handle 18, to the guide tip 241 is acomposite including flexible tubing 12 a ₁, which houses the lumen andoptical fiber (not separately shown in FIG. 6). Tubing 12 a ₁, may beplastic or metal (e.g., nitinol). A spring member 12 b ₁ surrounds theflexible shaft component 12 a ₁. The spring member 12 b ₁ is formed ofany suitable biocompatible material (such as nitinol or the like). Theshaft 12 ₁ can be bent and shaped at the desire of an operator tocontrol the degree of bending and the relative angle between the guidetip 24 ₁ and the shaft 12 ₁ and to hold such shape after bending. Thespring 12 b ₁ prevents kinking of a metal tube 12 a ₁ and maintainscircularity of cross-section.

FIGS. 7 and 8 show an alternative embodiment where the shaft 12 ₂includes two components including a rigid outer sleeve 12 a ₂ and aflexible, pre-formed inner tube 12 b ₂, which contains the lumen 26 ₂housing the fiber (not separately shown). The inner sleeve 12 b ₂ may beformed of pre-bent nitinol or plastic, which can be drawn into the outershaft 12 a ₂, which has a straight configuration. When the inner shaft12 b ₂ is moved relative to the rigid outer shaft 12 a ₂, the innershaft 12 b ₂ returns, by the bias of its material, to the bentconfiguration shown in phantom lines in FIG. 7.

In FIG. 9, the shaft 12 ₃ includes a series of articulating bellows 12 a₃ which can be bent and manipulated by an operator to achieve a desiredrelative angle between the handle 18 ₃ and guide tip 24 ₃.

In FIGS. 10 and 11, the shaft includes two lumens 26 ₄, 26 a ₄ with alarger lumen 26 ₄ housing the fiber (not shown) and a smaller lumen 26 a₄ containing a nitinol or other deformable rod or wire, which can bebent at the desire of an operator for a desired angle. This designpermits compound curves in the shaft 12 ₄.

FIGS. 12 and 13 show an embodiment where the shaft 12 ₅ includes a wirebraiding 12 a ₅ sandwiched between inner sheath and outer plastic sheath12 b ₅, 12 c ₅. The inner sheath 12 b ₅ defines the lumen 26 ₅ whichcontains the optical fiber (not shown). Both of the sheathings 12 b ₅,12 c ₅ are flexible plastic construction. The operator can then bend theshaft 12 ₅ with the braiding 12 a ₅ maintaining the desired angle ofcurvature.

FIGS. 14 and 15 show an embodiment similar to that of FIGS. 10 and 11except the second lumen 26 a ₆ contains a pull wire 12 a ₆ extendingfrom a knob 18 a ₆ to the guide tip 24 ₆. Pulling on the wire 12 a ₆ byturning the knob 18 a ₆ bends the guide tip 24 ₆ from a straightorientation (shown in phantom lines) to a curved orientation. Thisdesigns permits changing shape without re-positioning the location ofthe guide tip on the heart.

Imaging Capabilities

In addition to manipulating the angle of the guide tip 24, it may bedesirable to clearly visualize the target area of tissue being ablatedby the present invention. It has previously been described that avisually perceptible wavelength can be passed through the fiber 20simultaneous with a therapeutic wavelength. However, the operator maynot have adequate positioning relative to the guide tip 24 to fully viewand inspect the ablation procedure. In such cases, it is desirable toadd a second optical fiber to the laser wand to permit light to bepassed back to the fiber to a camera or the like for permitting remotevisualization. FIG. 16 illustrates such an option with FIG. 17illustrating a modification for enhanced visualization. In theembodiments of FIGS. 16 and 17, elements in common with the previousdescribed embodiment are numbered identically throughout with theaddition of subscripts to distinguish the embodiments.

FIG. 16 shows an optical fiber 207 carried on an external surface of theshaft 12 ₇. A distal end 22 a ₇ of the imaging optical fiber 20 a ₇ iscarried on the distal end of the shaft 12 ₇ by an inflatable balloon 14₇. Inflation of the balloon 14 ₇ permits the operator to control therelative positioning of the imaging fiber tip 22 a ₇ relative to theguide tip 24 ₇ to enlarge the field of view as desired.

In FIG. 17, a mirror 20 a ₈ is carried on a malleable mounting post 12 a₈ at the distal end of the shaft 12 ₈. The mounting post 12 a ₈ can bepre-manipulated by an operator for targeting an area to be inspectedthrough the mirror 20 a ₈ or use the mirror to reflect light to thetarget area.

Optional Conductivity Testing

As previously mentioned, it would be helpful if the surgeon couldpromptly discern whether a particular linear lesion is trulynon-conducting at the time of the original procedure to permitcorrection at that time. This would enable prompt re-treatment ifnecessary. FIGS. 19 and 20 illustrate alternative embodiments of such anoption. In FIGS. 19 and 20, elements in common with the structure ofFIG. 3 are similar numbered with the addition of an apostrophe (in thecase of FIG. 19) or double apostrophes (in the case of FIG. 20) todistinguish embodiments.

Unlike the previously described embodiments, a first electrode 50 a′ anda second electrode 50 b′ are preferably located on diametricallyopposite sides of lumen 29′ at the distal edge 50′ to contact the heartsurface for purposes that will be described. First electrode 50 a′ andsecond electrode 50 b′ are preferably separated by a distance on theorder of several millimeters, preferably 3 to 6 mm. The distanceselected is appropriate to ascertain that first electrode 50 a′ andsecond electrode 50 b′ can be readily applied to opposite sides of alinear lesion produced by the laser surgical wand. First electrode 50 a′and second electrode 50 b′ are selected and adapted to sense anelectrical potential in the local area of each.

Referring to FIG. 20, an alternative embodiment is shown includingextension structures 51 a″, 51 b″ that are mechanically attached to thedistal edge 50″ of the guide tip 24″. The extension structures 51 a″, 51b″ support the electrodes 50 a″, 50 b″ at an increased distance from theguide tip 24″. This arrangement provides greater spacing between theelectrodes 50 a″, 50 b″ which permits more extensive testing fortransmurality and electrical isolation of the lesion created by cardiacablation.

With the embodiment of FIGS. 19 and 20, the surgeon performs the MAZEprocedure as previously described without any use or activation of theelectrodes 50 a′, 50 b′ or 50 a″, 50 b″.

Upon completion of the procedure, the surgeon retraces the created lineswith laser surgical wand 10 so that first electrode 50 a′ or 50 a″ is onone side of the line and second electrode 50 b′ or 50 b″ is on theopposite side of the line. Electrical stimuli are then transmitted tothe electrodes 50 a′, 50 b′ or 50 a″, 50 b″ from electrophysiologymonitoring equipment 36 (FIG. 2) or similar instrumentation which areconnected to the laser surgical wand using coupling 28. Electricalconductors (not shown) are formed into the shaft 12′, 12″ andelectrically connect the coupling 28 to the electrodes 50 a′, 50 b′ or50 a″, 50 b″.

The response of the cardiac tissue is observed. Tracing the createdlines in this manner allows the surgeon to test to insure that twodifferent electrical potentials exist on either side of the line.Differing electrical potentials indicate that a complete blockage ofelectrical energy transmission has been obtained. In the event differentpotentials are not indicated, the procedure of applying laser energy tothe surface of the heart may be repeated as necessary until the desiredeffect of different potentials are obtained.

A major advantage of the current invention is the ability to createtransmural lesions with full cardiac flow present, i.e. on a beatingheart in an atraumatic manner without risk of perforation. With abeating heart, electrical isolation testing can optionally be done and,if gaps are found as evidence by lack of electrical isolation, thesegaps can be repaired with additional application of laser energy. Withradio frequency energy, the heart must be stopped which terminates allelectrical activity. Thus, it is not possible to perform electricalisolation testing at the time of lesion creation. This essentiallyprecludes repairing a failed line to obtain complete isolation unlessthe patient is placed on bypass a second time which is highlyundesirable and unlikely. As a result, these patients remain in somedegree of atrial fibrillation after surgery.

Another advantage of laser energy system and technique of the presentinvention is that it can be done concurrently with other beating heartprocedures.

The present invention in other specific forms without departing from thespirit of any of the essential attributes thereof. Therefore, theillustrated embodiments should be considered, in all respects, asillustrative and not restrictive, reference being made to the appendedclaims rather than to the forgoing description to indicate the scope ofthe invention.

Optional Multiple Fibers

Referring to FIG. 18, a modification replaces a single optical fiber 20with a multiple of smaller fibers 20 a, 20 b, 20 c, 20 d. The fibers 20a–20 d are placed collinear with the axis of the laser surgical wand.The use of multiple fibers 20 a–20 d focuses the laser energy whichincreases the probability of transmural lesions and also makes thelesion line thinner reducing the amount of cardiac tissue which isdamaged. The use of multiple fibers 20 a–20 d is also more conducive toa laparoscopic design since smaller fibers are more flexible and can bebent in a tighter radius.

With any of the foregoing embodiments, access to the surface of theheart could be to either the endocardial or epicardial surface. Accesscould be either through a sternotomy or less invasive port access orother surgical access (e.g., open heart to access endocardial tissue) orcould be catheter delivered. The procedure can be on a beating heart oron a heart with a patient supported on a by-pass machine.

In FIGS. 18–20, the collar 21 of FIG. 3 is not shown for ease ofillustration only.

It has been shown how the objects of the invention have been achieved ina preferred embodiment. It is intended that such modifications andequivalents which will appear to one of ordinary skill in the art withthe benefit of the teachings of the present invention shall be includedwithin the scope of the claims.

1. A method for treating a heart of a patient suffering from atrialfibrillation, said method comprising; a. identifying a patient withatrial fibrillation; b. accessing a surface of an atrium of the heart;c. positioning a lesion formation tool against said surface where saidtool includes: i. an optical fiber for guiding a coherent waveform of aselected wavelength to a fiber tip for discharge of coherent lightenergy from said fiber tip in a direction of energy discharge; ii. saidwavelength selected for said light energy to penetrate a thickness ofsaid tissue to a form a volume of necrosed tissue through a thickness ofsaid tissue, said wavelength selected to have a low absorption in water;d. moving said fiber tip over said surface in a pathway whilemaintaining a substantially constant spacing of said fiber tip from saidtissue to form a transmural lesion in said tissue extending a length ofsaid pathway; e. energizing said laser during said moving with anapplication of energy selected to form said lesion without perforationof said atrial tissue through a thickness of said atrial tissue.
 2. Amethod according to claim 1 wherein said wavelength is selected from arange of about 470 nm to about 900 nm.
 3. A method according to claim 2wherein said wavelength is selected from a range of about 790 nm toabout 850 nm.
 4. A method according to claim 3 wherein said wavelengthis about 805 nm.
 5. A method according to claim 1 wherein saidwavelength is selected from a range of about 1050 nm to about 1150 nm.6. A method according to claim 5 wherein said wavelength is selectedfrom a range of about 1050 nm to 1090 nm.
 7. A method according to claim1 wherein said surface is an epicardial surface.
 8. A method accordingto claim 1 wherein said surface is an endocardial surface.
 9. A methodaccording to claim 1 wherein a. said lesion formation tool furtherincludes: i. a guide member coupled to said fiber tip, said guide memberadapted to have a discharge bore aligned with said fiber tip and saiddirection of energy discharge to define an unobstructed light pathwayfrom the fiber tip to a discharge end of said discharge bore; ii. saidguide member further adapted to be placed against said tissue surfacewith said guide member slidable along said surface in atraumatic slidingengagement and with said end of said discharge bore opposing saidsurface; b. said method further including moving said guide member oversaid surface in a pathway while maintaining said discharge bore opposingsaid surface to form a transmural lesion in said tissue extending alength of said pathway.
 10. A method according to claim 1 wherein saidmoving includes manually moving said fiber tip over said surface.
 11. Amethod according to claim 1 wherein said light energy is provided at apower level between 5 watts and 50 watts.
 12. A method according toclaim 1 wherein said light energy is directed in an unobstructed pattoward said tissue.
 13. An apparatus for treating a heart of a patientsuffering from atrial fibrillation, said apparatus comprising: a. anoptical fiber for guiding a coherent waveform of a selected wavelengthto a fiber tip for discharge of light energy from said fiber Up in adirection of energy discharge; b. said wavelength selected for saidlight energy to penetrate a thickness of said tissue to form a volume ofnecrosed tissue through a thickness of said tissue; c. a smooth, curvedtissue engaging surface, adapted for atraumatic sliding movement overatrial tissue, said fiber tip in recess fixed spacing from the tissueengaging surface and said tip oriented to direct said light energydirectly toward said tissue engaging surface; d. said wavelengthselected to have a low absorption in water and applicable at a powerduring moving of said fiber tip over a surface of atrial tissue to formsaid volume without perforation of said atrial tissue though a thicknessof said atrial tissue.
 14. An apparatus according to claim 13 whereinsaid wavelength is selected from a range of about 470 nm to about 900nm.
 15. An-apparatus according to claim 14 wherein said wavelength isselected from a range of about 790 nm to about 850 nm.
 16. An apparatusaccording to claim 15 wherein said wavelength is about 805 nm.
 17. Anapparatus according to claim 13 wherein said wavelength is selected froma range of about 1050 nm to about 1150 nm.
 18. An apparatus according toclaim 17 wherein said wavelength is selected from a range of about 1050nm to 1090 nm.
 19. An apparatus according to claim 13 furthercomprising: a. a guide member coupled to said fiber tip, said guidemember having a discharge bore aligned with said fiber tip and saiddirection of energy discharge to define an unobstructed light pathwayfrom the fiber tip to a discharge end of said discharge bore; b. saidguide member farther adapted to be placed against a surface of saidtissue with said guide member slidable along said surface in atraumaticsliding engagement and with said end of said discharge bore opposingsaid surface.
 20. An apparatus according to claim 13 wherein said guidemember is a guide tip mounted to a handle for manual manipulation. 21.An apparatus according to claim 13 wherein said light energy is directedin an unobstructed path toward a tissue engaged by said tissue engagingsurface.